Everest Medicines Dirección

Dirección controles de criterios 2/4

El CEO de Everest Medicines es Rogers Luo , nombrado en Sep 2022, tiene una permanencia de 2.17 años. compensación anual total es CN¥30.72M, compuesta por 23.5% salario y 76.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.3% de las acciones de la empresa, por valor de HK$34.46M. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 3.2 años, respectivamente.

Información clave

Rogers Luo

Chief Executive Officer (CEO)

CN¥30.7m

Compensación total

Porcentaje del salario del CEO	23.5%
Permanencia del CEO	2.2yrs
Participación del CEO	0.3%
Permanencia media de la dirección	2.4yrs
Promedio de permanencia en la Junta Directiva	3.2yrs

Actualizaciones recientes de la dirección

Recent updates

Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?

Apr 27

Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year

Mar 31

A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

Jan 31

A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

Sep 26

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rogers Luo en comparación con los beneficios de Everest Medicines?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CN¥1b
Mar 31 2024	n/a	n/a	-CN¥949m
Dec 31 2023	CN¥31m	CN¥7m	-CN¥844m
Sep 30 2023	n/a	n/a	-CN¥424m
Jun 30 2023	n/a	n/a	-CN¥3m
Mar 31 2023	n/a	n/a	-CN¥125m
Dec 31 2022	CN¥8m	CN¥2m	-CN¥247m

Compensación vs. Mercado: La compensación total de Rogers($USD4.25M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD488.63K).

Compensación vs. Ingresos: La compensación de Rogers ha aumentado mientras la empresa no es rentable.

CEO

Rogers Luo (54 yo)

2.2yrs

Permanencia

CN¥30,722,000

Compensación

Mr. Yongqing Luo, also known as Rogers, is CEO & Executive Director of Everest Medicines Limited from September 19, 2022. He was President and General Manager of Greater China at Brii Biosciences Limited a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Fu Wei	Executive Chairman	7.3yrs	sin datos	0.59% HK$ 67.1m
Yongqing Luo	CEO & Executive Director	2.2yrs	CN¥30.72m	0.30% HK$ 34.5m
Ian Ying Woo	CFO, President & Executive Director	6.4yrs	CN¥18.46m	0.063% HK$ 7.1m
Jason M. Brown	Chief Business Officer	5.3yrs	sin datos	sin datos
Wei Yang	Chief Scientific Officer	3.6yrs	sin datos	sin datos
Steve Xu	Chief Legal & Compliance Officer	less than a year	sin datos	sin datos
Rico Liang	Chief Product Officer	less than a year	sin datos	sin datos
Sandra Zeng	Chief Medical Officer	less than a year	sin datos	sin datos
Yee Wa Lau	Joint Company Secretary	no data	sin datos	sin datos
Leah Liu	Joint Company Secretary & VP of Corporate Affairs	2.7yrs	sin datos	sin datos

2.4yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1952 se considera experimentado (2.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Fu Wei	Executive Chairman	7.3yrs	sin datos	0.59% HK$ 67.1m
Yongqing Luo	CEO & Executive Director	2.2yrs	CN¥30.72m	0.30% HK$ 34.5m
Ian Ying Woo	CFO, President & Executive Director	5.9yrs	CN¥18.46m	0.063% HK$ 7.1m
Yifan Li	Independent Non-Executive Director	4.2yrs	CN¥401.00k	sin datos
Ki Chul Cho	Non-Executive Director	less than a year	sin datos	sin datos
Shidong Jiang	Independent Non-Executive Director	4.2yrs	CN¥401.00k	sin datos
Hoi Yam Chui	Independent Non-Executive Director	1.8yrs	CN¥352.00k	sin datos
Honggang Feng	Non-Executive Director	less than a year	sin datos	sin datos

3.2yrs

Permanencia media

54.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 1952 se considera experimentada (3.2 años de antigüedad promedio).

Everest Medicines Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Everest Medicines Limited, Annual General Meeting, Jun 28, 2024

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

Everest Medicines Limited Announces Board Changes

Everest Medicines Limited Announces Directorate Changes

Everest Medicines Appoints Mike Berry as Chief Technology Officer

Everest Medicines Limited, Annual General Meeting, Jun 29, 2023

Recent updates

Everest Medicines Limited Announces Business Update on NEFECON Development

Now 21% undervalued

Now 24% undervalued

Consensus EPS estimates fall by 38%, revenue upgraded

First half 2024 earnings: Revenues in line with analyst expectations

Now 22% undervalued after recent price drop

New minor risk - Profitability

No longer forecast to breakeven

Everest Medicines Limited to Report First Half, 2024 Results on Aug 27, 2024

Now 21% undervalued after recent price drop

Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis

Everest Medicines Announces Official Acceptance Granted on NEFECON® Supplementary Application by China National Medical Products Administration

Everest Medicines Announces Positive Topline Results from Maintenance Period of Etrasimod Phase 3 Clinical Trial Conducted in Asia for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

Everest Medicines Limited, Annual General Meeting, Jun 28, 2024

Now 24% overvalued after recent price rise

Everest Medicines Announces Commercial Launch and First Prescription for NEFECON in Mainland China

Everest Medicines Announces New Drug Application Approval of Velsipity® for Adults with Moderately to Severely Active Ulcerative Colitis in Macau

Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon® for the Treatment for Primary IgA Nephropathy in Adult Patients

Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?

Now 22% overvalued after recent price rise

Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings released

Forecast to breakeven in 2026

Now 23% overvalued after recent price rise

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

Consensus revenue estimates increase by 28%

Everest Medicines Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Now 25% overvalued after recent price rise

Everest Medicines Limited Announces Board Changes

Now 23% undervalued after recent price drop

A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)

Consensus revenue estimates increase by 17%

Everest Medicines Limited Provides Earning Guidance for the Year Ended 31 December 2023

Everest Medicines Limited Announces Directorate Changes

Everest Medicines Announces New Drug Application Acceptance of Nefecon® in Taiwan for the Treatment of Primary IgA Nephropathy in Adult Patients

Everest Medicines Reaffirms Revenue Guidance for the Year 2023 and 2024

Calliditas’ Partner Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy

National Medical Products Administration Approves the New Drug Application for Nefecon for the Treatment of Primary Immunoglobulin A Nephropathy in Adults At Risk of Disease Progress in China

Everest Medicines Announces New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy

Everest Medicines Limited Announces Approval of XERAVA® in Taiwan for the Treatment of Complicated Intra-Abdominal Infections in Adult Patients

Consensus revenue estimates decrease by 16%, EPS upgraded

First half 2023 earnings released: CN¥1.40 loss per share (vs CN¥2.26 loss in 1H 2022)

Everest Medicines Announces New Drug Application Acceptance by the Pharmaceutical Administration Bureau of Macao for Nefecon(R) for the Treatment of Primary IgA Nephropathy

Everest Medicines Limited to Report First Half, 2023 Results on Aug 24, 2023

Everest Medicines Announces Completion of Patient Enrollment in Nefecon®? China Open Label Extension Study

Everest Medicines Announces Commercial Launch and First Prescription for XERAVA in China

Everest Medicines Appoints Mike Berry as Chief Technology Officer

New major risk - Share price stability

Everest Medicines Limited, Annual General Meeting, Jun 29, 2023

Everest Medicines Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Etrasimod in Asia

Consensus revenue estimates increase by 151%

Consensus revenue estimates decrease by 17%

No longer forecast to breakeven

Consensus estimates of losses per share improve by 91%

Everest Medicines Announces South Korea Grants Fast Track Review Designation to Nefecon for the Treatment of Primary Iga Nephropathy

Consensus EPS estimates fall by 593%

Everest Medicines Limited Announces Board Changes

Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China

Consensus revenue estimates fall by 28%

Everest Medicines Aims to Initiate Clinical Trials and File an Emergency Use Authorization Application in 2023 in China for Its Lead mRNA Candidate

Everest Medicines Announces China NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Everest Medicines Announces Major Regulatory Updates in Taiwan and South Korea for Nefecon for the Treatment of Primary IgA Nephropathy

Less than half of directors are independent

Everest Medicines Announces New Drug Application Acceptance by China NMPA for Nefecon for the Treatment of Primary IgA Nephropathy

Everest Medicines Announces Approval of XERAVA in Hong Kong for the Treatment of Complicated Intra-Abdominal Infections

Forecast to breakeven in 2022

Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001

Everest Medicines Appoints Rogers Yongqing Luo as an Executive Director